Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | NPC1 | O15118 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MIF | P14174 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15672293 | 0.85 | RAB9A (0.64) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL15672263 | 0.80 | RAB9A (0.66) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL11564698 | 0.78 | LMNA (0.47) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL14938615 | 0.77 | ALDH1A1 (0.59) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL10431722 | 0.77 | LMNA (0.43) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL14938617 | 0.77 | ALDH1A1 (0.59) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL9656862 | 0.77 | NPC1 (0.69) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL9656857 | 0.77 | NPC1 (0.69) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL12979794 | 0.76 | MAPT (0.76) | RAB9ASMN1; SMN2NPC1MEN1KMT2A | |
| SCHEMBL3266677 | 0.76 | MAPT (0.76) | RAB9ASMN1; SMN2NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210047278-A1 | E3 UBIQUITIN LIGASE AGONISTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE E3 UBIQUITIN LIGASE AGONISTS, RELATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047278-A1 | E3 UBIQUITIN LIGASE AGONISTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE E3 UBIQUITIN LIGASE AGONISTS, RELATED METHODS OF USE | UBE3A, NEDD4, ADRM1 | RAB9A 2641/4885SMN1; SMN2 3037/4885NPC1 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.